Professor Georgina Long AO
BSc PhD MBBS FRACP FAHMS AAHMS FAA FASCO
Medical Director & Medical Oncologist
Professor Georgina Long AO, BSc (Hons1, UM) PhD MBBS (Hons) FRACP FAHMS AAHMS FAA FASCO, is Medical Director of Melanoma Institute Australia (MIA), and Chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, The University of Sydney. She leads an extensive clinical trials team and laboratory at MIA, with a focus on immuno-oncology and targeted therapies in melanoma. She is principal investigator on phase I, II and III clinical trials in (neo)adjuvant and metastatic melanoma, including trials in patients with active brain metastases. She is the chief investigator on NHMRC funded research into the molecular biology of melanoma, with a particular interest in clinical and tissue biomarker correlates of systemic therapy sensitivity and resistance.
In recognition of her ground-breaking research and work, Professor Long was named 2024 Australian of the Year and was awarded prestigious Fellowships with the American Society for Clinical Oncology (2025), the Australian Academy of Science (2024) and the Australian Academy of Health and Medical Sciences (2017), the latter awarding her the Outstanding Female Research Medal (2021). Professor Long was appointed as an Officer of the Order of Australia (2020) and has received numerous awards, including Fulbright U.S. Mission Australia Award for Leadership Excellence (2024), Estela Medrano Melanoma Award (2024), ESMO Women for Oncology Award (2023), Sydney Local Health District/Sydney Research 2022 Research Excellence Award (2022) the prestigious Ramaciotti Medal for Biomedical Research (2021), Vice Chancellor’s Award for Excellence Award for Outstanding Research (2021), University of Sydney (2021), Research Australia GSK Research Excellence Award (2018) and the Sir Zelman Cowen Universities Fund Prize for Discovery in Medical Research (2016). She has a number of CINSW Premiers Awards, including: the Outstanding Cancer Researcher (2018), the Excellence in Translational Cancer Research Award (2017), the Wildfire Award for the most highly-cited, original, peer-reviewed article published (2011, 2014, 2016, 2017, 2018, 2019 & 2020), and in 2013 she was named the Outstanding Cancer Research Fellow. She is a Clarivate highly-cited Researcher from 2017, with an H index of 155.
Professor Long is the author of over 610 peer-reviewed publications in clinical and translational research in melanoma, including the New England Journal of Medicine, Lancet, Lancet Oncology, Science, Nature, Nature Medicine, Journal of Clinical Oncology and Cancer Discovery. Professor Long has presented her work at international conferences and meetings on more than 300 occasions. She was President for the prestigious international Society for Melanoma Research (President 2018-2020), is a member and Chair of the ASCO (2015-2017) and ESMO (2017-2020 & 2026 – 2029) Scientific Committee for Melanoma/Skin cancer, is medical oncology lead for the Australian Melanoma Management Guidelines Committee, and is member of both the ASCO Plenary Series and ASCO AGM Education committees (2021-2024), Scientific Co-Chair for ESMO Asia (2024) and EADO (2026), she is on the editorial boards of several high-impact journals, and is a member of the Melanoma Expert Panel for AJCC Cancer Staging System 8th edition.
Professor Long was awarded the University Medal in Organic Chemistry. She subsequently completed her PhD in Chemistry in the field of anti-cancer agents and their binding to DNA. She then moved to the USA to take up a Fulbright Postdoctoral Fellowship at Scripps Research Institute, exploring nanotechnology in cancer treatment, before returning to Australia to complete her MBBS (Hons). Professor Long became a Fellow of the Australasian College of Physicians in January 2008, specialising in medical oncology.
Contact details
For all media enquiries, please email media@melanoma.org.au
To make a medical appointment to see Prof Georgina Long AO, or for any clinical concerns, please email smo_reception@melanoma.org.au
To contact Professor Georgina Long AO on all other matters, please email her Executive Assistant at ealong@melanoma.org.au
Prof Long Recent News
From just 16 weeks’ survival to long term disease control
Newly released long-term data from a groundbreaking clinical trial for advanced melanoma patients whose disease had spread to their brain has proven that long-term disease control has been achieved for over 50% of patients given combination immunotherapy as first line treatment.
$2.1 million to help boost cancer research in NSW
This World Cancer Research Day, the NSW Government is committing $2.1 million in research grant funding, with almost $700k awarded to MIA's Prof Long for an imaging system that will allow researchers to better visualise & understand tumour cell interactions.
MIA researchers sharing world stage at ESMO24
MIA’s leading experts and early career researchers have shared the world stage at the annual European Society for Medical Oncology (ESMO) Congress in Barcelona.
Preventing disease recurrence in BRAF positive melanoma patients
Final results of the COMBI-AD clinical trial, published in New England Journal of Medicine, show significant benefit in preventing disease progression in BRAF positive Stage III melanoma patients.
Prof Long Recent Publications
Kirkwood JM, Mohr P, Hoeller C, Grob J-J, Del Vecchio M, Lord-Bessen J, Srinivasan S, Nassar A, Campigotto F, Fairbanks H, Taylor F, Lawrance R, Long GV, Weber J. European Journal of Cancer, 220(2025/05/02/ 2025): 115371, doi:https://doi.org/10.1016/j.ejca.2025.115371.
Syeda MM, Long GV, Garrett J, Atkinson V, Santinami M, Schadendorf D, Hauschild A, Millward M, Mandala M, Chiarion-Sileni V, Smylie M, Manikhas GM, Dummer R, Wiggins JM, Ali S, Adnaik SB, Tan M, Dajee M, Polsky D. The Lancet Oncology, (Apr 15 2025), doi:10.1016/S1470-2045(25)00139-1.
Braden J, Potter A, Rawson RV, Adegoke NA, Lo SN, Conway JW, Menzies AM, Carlino MS, Au-Yeung G, Saw RPM, Spillane AJ, Shannon KF, Pennington TE, Ch’ng S, Gyorki DE, Howle JR, Wilmott JS, Scolyer RA, Long GV, Pires da Silva I. Modern Pathology, (Apr 14 2025): 100776, doi:https://doi.org/10.1016/j.modpat.2025.100776. TOP 10%
Grover P, Lo SN, Li I, Kuijpers AMJ, Kreidieh F, Williamson A, Amaral T, Dimitriou F, Placzke J, Olino K, Vitale MG, Saiag P, Gutzmer R, Allayous C, Bagge RO, Mattsson J, Asher N, Carter TJ, Meniawy TM, Lawless AR, Czapla JA, Warburton L, Gaudy-Marquest C, Grob JJ, Collins RG, Zhang E, Kessels JI, Neyns B, Mehmi I, Hamid O, Julve M, Furness AJS, Margolin KA, Levi-Ari S, Ressler JM, Haque W, Khattak MA, Wicky A, Roberts-Thomson R, Arance A, Warrier G, Schollenberger MD, Parente P, Chatziioannou E, Lipson EJ, Michielin O, Weber JS, Hoeller C, Larkin J, Atkins MB, Essner R, Johnson DB, Sullivan RJ, Nathan P, Schachter J, Lebbe C, Ascierto PA, Kluger H, Rutkowski P, Dummer R, Garbe C, Lorigan PC, Burton E, Tawbi HA, Haanen J, Carlino MS, Menzies AM, Long GV. Annals of Oncology, (Apr 08 2025), doi:https://doi.org/10.1016/j.annonc.2025.03.021.
Bührer E, Glassee N, Kicinski M, Kennedy OJ, Blank CU, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Boers-Sonderen M, Di Giacomo AM, van den Eertwegh AJM, Grob J-J, Gutzmer R, Jamal R, van Akkooi ACJ, Gandini S, Valpione S, Suciu S, Robert C, Eggermont AMM, Lorigan P, Mandala M. EJC Skin Cancer, (Mar 27 2025): 100727, doi:https://doi.org/10.1016/j.ejcskn.2025.100727.
Luke JJ, Ascierto PA, Khattak MA, Rutkowski P, Del Vecchio M, Spagnolo F, Mackiewicz J, Merino LdlC, Chiarion-Sileni V, Kirkwood JM, Robert C, Schadendorf D, de Galitiis F, Carlino MS, Dummer R, Mohr P, Odeleye-Ajakaye A, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Long GV. European Journal of Cancer, (Mar 23 2025): 115381, doi:https://doi.org/10.1016/j.ejca.2025.115381.
Fletcher KA, Goodman RS, Lawless A, Woodford R, Fa’ak F, Tipirneni A, Patrinely JR, Yeoh HL, Rapisuwon S, Haydon A, Osman I, Mehnert JM, Long GV, Sullivan RJ, Carlino MS, Menzies AM, Dewan AK, Johnson DB. JAMA Dermatol, (Mar 12 2025), doi:10.1001/jamadermatol.2025.0025. TOP 10%
Long GV, Lipson EJ, Hodi FS, Ascierto PA, Larkin J, Lao C, Grob J-J, Ejzykowicz F, Moshyk A, Garcia-Horton V, Zhou Z-Y, Xin Y, Palaia J, McDonald L, Keidel S, Salvatore A, Patel D, Sakkal LA, Tawbi H, Schadendorf D. Journal of Clinical Oncology, 0, no. 0, (Mar 07 2025): JCO-25-00452, doi:10.1200/jco-25-00452. TOP 10%
Nassar AH, Abou Alaiwi S, El Zarif T, Denu R, Macaron W, Abdel-Wahab N, Freeman D, Vasbinder A, Hayeck S, Anderson E, Goodman RS, Johnson DB, Grynberg S, Shapira R, Kwan JM, Woodford R, Long GV, Haykal T, Dent S, Kojima Y, Yonemor K, Tandon A, Trevino A, Akhter N, Yang EH, Hui G, Drakaki A, El-Am E, Kozaily E, Al-Hader A, Bou Farhat E, Babu P, Mittra A, Li M, Jones N, Baena J, Juarez Herrera M, Foderaro S, Nana FA, Kim C, Sackstein P, Parikh K, Desai AP, Smith C, Cortellini A, Pinato DJ, Korolewicz J, Lopetegui-Lia N, Funchain P, Choudhary A, Asnani A, Navani V, Meyers D, Stukalin I, Ocejo Gallegos JA, Trent J, Nusrat S, Malvar C, McKay RR, Neilan TG, Choueiri TK, Naqash AR. J Immunother Cancer, 13, no. 3, (Mar 3 2025), doi:10.1136/jitc-2024-009364.
Zhou L, Barros e Silva MJ, Hsiao E, Eroglu Z, Sandhu S, Samoylenko I, Lo SN, Carlino MS, Au-Yeung G, Gonzalez M, Spillane AJ, Pennington TE, Shannon KF, Kapoor R, Burton EM, Tawbi HA, Amaria RN, Blank CU, Duprat JP, Brito de Paula R, Gyorki DE, Saw RPM, Ch’Ng S, Rawson RV, Scolyer RA, Pires da Silva I, Akkooi ACJv, Long GV, Menzies AM. Journal for ImmunoTherapy of Cancer, 13, no. 3, (Mar 25 2025): e011483, doi:10.1136/jitc-2025-011483.
ZERO DEATHS FROM MELANOMA
Suzanne Sherwood says:
Steve Cole says:
Catherine Mardell says: